BETA
Home MEPs Dossiers Committees Subjects Blog About Dumps
download json


2024/2606(DEA) Inclusion of the drug precursor Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (IMDPAM) and other substances in the list of scheduled substances

Progress: Procedure completed - delegated act enters into force

RoleCommitteeRapporteurShadows
Lead LIBE LÓPEZ AGUILAR Juan Fernando (icon: S&D S&D)
Lead committee dossier:
Legal Basis:
R, u, l, e, s, , o, f, , P, r, o, c, e, d, u, r, e, , E, P, , 0, 1, 1, 4, -, p, 6

Events

2024/04/23
   EP - Decision by Parliament
Details

The European Parliament decided to raise no objections to the Commission delegated regulation of 28 February 2024 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of the drug precursor Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (IMDPAM) and other substances in the list of scheduled substances.

The EU legislative framework on measures to control access to substances used in the manufacture of illicit drugs must be continuously updated to counter the proliferation of the so-called ‘designer precursors’, which are close chemical relatives of traditional drug precursors created to circumvent existing rules.

The sodium salt of Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (IMDPAM) has been identified as a newly developed drug precursor used in the production of MDMA (3,4-methylenedioxymethamphetamine), commonly known as ‘ecstasy’. Seven esters of 2-methyl-3-phenyloxirane-2-carboxylic acid (BMK glycidic acid) and six esters of 3-(1,3-benzodioxol-5-yl)-2-methyl-oxirane-2-carboxylic acid (PMK glycidic acid) have been identified as possible substitutes of BMK glycidic acid and PMK glycidic acid, which are controlled precursors under EU law, in the production of illicit drugs such as MDMA, methamphetamine and amphetamine.

It is necessary to amend the list of scheduled substances included in Annex I to Regulation (EC) No 273/2004 and in the Annex to Regulation (EC) No 111/2005 to subject IMDPAM and the identified esters of BMK glycidic acid and PMK glycidic acid to the harmonised control and monitoring measures provided for by those regulations.

Measures to control access to newly scheduled substances under Regulations (EC) No 273/2004 and (EC) No 111/2005 should enter into force as soon as possible to prevent the use of those drug precursors for the production and placing on the market of illicit drugs.

Against this background, Parliament declared that it has no objections to the delegated regulation.

Text adopted by Parliament, single reading

Documents
T9-0314/2024
2024/04/12
   CSL - Delegated act not objected by Council
2024/04/10
   European Parliament - Recommendation for early non-objection of delegated act
Documents
B9-0213/2024
2024/04/04
   EP - LÓPEZ AGUILAR Juan Fernando (S&D) appointed as rapporteur in LIBE
2024/03/13
   EP - Committee referral announced in Parliament
2024/02/28
   European Commission - Non-legislative basic document
Documents
C(2024)01219
2024/02/28
   EC - Non-legislative basic document published
Documents
C(2024)01219
2024/02/28
   Initial period for examining delegated act 2.0 month(s)

Documents

History

(these mark the time of scraping, not the official date of the change)

2024-12-18Show (12) Changes | Timetravel
committees/0/rapporteur/0/group
Old
Group of Progressive Alliance of Socialists and Democrats
New
Progressive Alliance of Socialists and Democrats
docs/0
date
2024-02-28T00:00:00
docs
url: https://webgate.ec.europa.eu/regdel/web/delegatedActsLinks/C(2024)01219 title: C(2024)01219
type
Non-legislative basic document
body
EC
docs/0
date
2024-04-10T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/B-9-2024-0213_EN.html title: B9-0213/2024
type
Recommendation for early non-objection of delegated act
body
EP
docs/0/body
Old
EP
New
European Parliament
docs/1
date
2024-02-28T00:00:00
docs
url: https://webgate.ec.europa.eu/regdel/web/delegatedActsLinks/C(2024)01219 title: C(2024)01219
type
Non-legislative basic document
body
EC
docs/1
date
2024-04-10T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/B-9-2024-0213_EN.html title: B9-0213/2024
type
Recommendation for early non-objection of delegated act
body
EP
docs/1/body
Old
EC
New
European Commission
events/1
date
2024-02-28T00:00:00
type
Initial period for examining delegated act 2.0 month(s)
events/1
date
2024-02-28T00:00:00
type
Initial period for examining delegated act 2 month(s)
body
EP/CSL
events/4/summary/6
Text adopted by Parliament, single reading
procedure/dossier_of_the_committee
Old
  • LIBE/9/14299
New
LIBE/9/14299
procedure/legal_basis
Old
  • Rules of Procedure EP 0114-p6
New
Rules of Procedure EP 0114-p6
2024-07-11Show (2) Changes | Timetravel
procedure/legal_basis/0
Rules of Procedure EP 0114-p6
procedure/legal_basis/0
Rules of Procedure EP 0111-p6
2024-07-10Show (2) Changes | Timetravel
procedure/legal_basis/0
Rules of Procedure EP 0114-p6
procedure/legal_basis/0
Rules of Procedure EP 0111-p6
2024-07-09Show (2) Changes | Timetravel
procedure/legal_basis/0
Rules of Procedure EP 0114-p6
procedure/legal_basis/0
Rules of Procedure EP 0111-p6
2024-07-08Show (2) Changes | Timetravel
procedure/legal_basis/0
Rules of Procedure EP 0114-p6
procedure/legal_basis/0
Rules of Procedure EP 0111-p6
2024-07-07Show (2) Changes | Timetravel
procedure/legal_basis/0
Rules of Procedure EP 0114-p6
procedure/legal_basis/0
Rules of Procedure EP 0111-p6
2024-07-06Show (2) Changes | Timetravel
procedure/legal_basis/0
Rules of Procedure EP 0114-p6
procedure/legal_basis/0
Rules of Procedure EP 0111-p6
2024-06-08Show (2) Changes | Timetravel
docs/2
date
2024-04-23T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0314_EN.html title: T9-0314/2024
type
Text adopted by Parliament, single reading
body
EP
events/4/summary
  • The European Parliament decided to raise no objections to the Commission delegated regulation of 28 February 2024 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of the drug precursor Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (IMDPAM) and other substances in the list of scheduled substances.
  • The EU legislative framework on measures to control access to substances used in the manufacture of illicit drugs must be continuously updated to counter the proliferation of the so-called ‘designer precursors’, which are close chemical relatives of traditional drug precursors created to circumvent existing rules.
  • The sodium salt of Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (IMDPAM) has been identified as a newly developed drug precursor used in the production of MDMA (3,4-methylenedioxymethamphetamine), commonly known as ‘ecstasy’. Seven esters of 2-methyl-3-phenyloxirane-2-carboxylic acid (BMK glycidic acid) and six esters of 3-(1,3-benzodioxol-5-yl)-2-methyl-oxirane-2-carboxylic acid (PMK glycidic acid) have been identified as possible substitutes of BMK glycidic acid and PMK glycidic acid, which are controlled precursors under EU law, in the production of illicit drugs such as MDMA, methamphetamine and amphetamine.
  • It is necessary to amend the list of scheduled substances included in Annex I to Regulation (EC) No 273/2004 and in the Annex to Regulation (EC) No 111/2005 to subject IMDPAM and the identified esters of BMK glycidic acid and PMK glycidic acid to the harmonised control and monitoring measures provided for by those regulations.
  • Measures to control access to newly scheduled substances under Regulations (EC) No 273/2004 and (EC) No 111/2005 should enter into force as soon as possible to prevent the use of those drug precursors for the production and placing on the market of illicit drugs.
  • Against this background, Parliament declared that it has no objections to the delegated regulation.
2024-06-07Show (2) Changes | Timetravel
docs/2
date
2024-04-23T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0314_EN.html title: T9-0314/2024
type
Text adopted by Parliament, single reading
body
EP
events/4/summary
  • The European Parliament decided to raise no objections to the Commission delegated regulation of 28 February 2024 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of the drug precursor Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (IMDPAM) and other substances in the list of scheduled substances.
  • The EU legislative framework on measures to control access to substances used in the manufacture of illicit drugs must be continuously updated to counter the proliferation of the so-called ‘designer precursors’, which are close chemical relatives of traditional drug precursors created to circumvent existing rules.
  • The sodium salt of Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (IMDPAM) has been identified as a newly developed drug precursor used in the production of MDMA (3,4-methylenedioxymethamphetamine), commonly known as ‘ecstasy’. Seven esters of 2-methyl-3-phenyloxirane-2-carboxylic acid (BMK glycidic acid) and six esters of 3-(1,3-benzodioxol-5-yl)-2-methyl-oxirane-2-carboxylic acid (PMK glycidic acid) have been identified as possible substitutes of BMK glycidic acid and PMK glycidic acid, which are controlled precursors under EU law, in the production of illicit drugs such as MDMA, methamphetamine and amphetamine.
  • It is necessary to amend the list of scheduled substances included in Annex I to Regulation (EC) No 273/2004 and in the Annex to Regulation (EC) No 111/2005 to subject IMDPAM and the identified esters of BMK glycidic acid and PMK glycidic acid to the harmonised control and monitoring measures provided for by those regulations.
  • Measures to control access to newly scheduled substances under Regulations (EC) No 273/2004 and (EC) No 111/2005 should enter into force as soon as possible to prevent the use of those drug precursors for the production and placing on the market of illicit drugs.
  • Against this background, Parliament declared that it has no objections to the delegated regulation.
2024-06-06Show (2) Changes | Timetravel
docs/2
date
2024-04-23T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0314_EN.html title: T9-0314/2024
type
Text adopted by Parliament, single reading
body
EP
events/4/summary
  • The European Parliament decided to raise no objections to the Commission delegated regulation of 28 February 2024 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of the drug precursor Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (IMDPAM) and other substances in the list of scheduled substances.
  • The EU legislative framework on measures to control access to substances used in the manufacture of illicit drugs must be continuously updated to counter the proliferation of the so-called ‘designer precursors’, which are close chemical relatives of traditional drug precursors created to circumvent existing rules.
  • The sodium salt of Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (IMDPAM) has been identified as a newly developed drug precursor used in the production of MDMA (3,4-methylenedioxymethamphetamine), commonly known as ‘ecstasy’. Seven esters of 2-methyl-3-phenyloxirane-2-carboxylic acid (BMK glycidic acid) and six esters of 3-(1,3-benzodioxol-5-yl)-2-methyl-oxirane-2-carboxylic acid (PMK glycidic acid) have been identified as possible substitutes of BMK glycidic acid and PMK glycidic acid, which are controlled precursors under EU law, in the production of illicit drugs such as MDMA, methamphetamine and amphetamine.
  • It is necessary to amend the list of scheduled substances included in Annex I to Regulation (EC) No 273/2004 and in the Annex to Regulation (EC) No 111/2005 to subject IMDPAM and the identified esters of BMK glycidic acid and PMK glycidic acid to the harmonised control and monitoring measures provided for by those regulations.
  • Measures to control access to newly scheduled substances under Regulations (EC) No 273/2004 and (EC) No 111/2005 should enter into force as soon as possible to prevent the use of those drug precursors for the production and placing on the market of illicit drugs.
  • Against this background, Parliament declared that it has no objections to the delegated regulation.
2024-06-05Show (2) Changes | Timetravel
docs/2
date
2024-04-23T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0314_EN.html title: T9-0314/2024
type
Text adopted by Parliament, single reading
body
EP
events/4/summary
  • The European Parliament decided to raise no objections to the Commission delegated regulation of 28 February 2024 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of the drug precursor Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (IMDPAM) and other substances in the list of scheduled substances.
  • The EU legislative framework on measures to control access to substances used in the manufacture of illicit drugs must be continuously updated to counter the proliferation of the so-called ‘designer precursors’, which are close chemical relatives of traditional drug precursors created to circumvent existing rules.
  • The sodium salt of Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (IMDPAM) has been identified as a newly developed drug precursor used in the production of MDMA (3,4-methylenedioxymethamphetamine), commonly known as ‘ecstasy’. Seven esters of 2-methyl-3-phenyloxirane-2-carboxylic acid (BMK glycidic acid) and six esters of 3-(1,3-benzodioxol-5-yl)-2-methyl-oxirane-2-carboxylic acid (PMK glycidic acid) have been identified as possible substitutes of BMK glycidic acid and PMK glycidic acid, which are controlled precursors under EU law, in the production of illicit drugs such as MDMA, methamphetamine and amphetamine.
  • It is necessary to amend the list of scheduled substances included in Annex I to Regulation (EC) No 273/2004 and in the Annex to Regulation (EC) No 111/2005 to subject IMDPAM and the identified esters of BMK glycidic acid and PMK glycidic acid to the harmonised control and monitoring measures provided for by those regulations.
  • Measures to control access to newly scheduled substances under Regulations (EC) No 273/2004 and (EC) No 111/2005 should enter into force as soon as possible to prevent the use of those drug precursors for the production and placing on the market of illicit drugs.
  • Against this background, Parliament declared that it has no objections to the delegated regulation.
2024-06-04Show (2) Changes | Timetravel
docs/2
date
2024-04-23T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0314_EN.html title: T9-0314/2024
type
Text adopted by Parliament, single reading
body
EP
events/4/summary
  • The European Parliament decided to raise no objections to the Commission delegated regulation of 28 February 2024 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of the drug precursor Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (IMDPAM) and other substances in the list of scheduled substances.
  • The EU legislative framework on measures to control access to substances used in the manufacture of illicit drugs must be continuously updated to counter the proliferation of the so-called ‘designer precursors’, which are close chemical relatives of traditional drug precursors created to circumvent existing rules.
  • The sodium salt of Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (IMDPAM) has been identified as a newly developed drug precursor used in the production of MDMA (3,4-methylenedioxymethamphetamine), commonly known as ‘ecstasy’. Seven esters of 2-methyl-3-phenyloxirane-2-carboxylic acid (BMK glycidic acid) and six esters of 3-(1,3-benzodioxol-5-yl)-2-methyl-oxirane-2-carboxylic acid (PMK glycidic acid) have been identified as possible substitutes of BMK glycidic acid and PMK glycidic acid, which are controlled precursors under EU law, in the production of illicit drugs such as MDMA, methamphetamine and amphetamine.
  • It is necessary to amend the list of scheduled substances included in Annex I to Regulation (EC) No 273/2004 and in the Annex to Regulation (EC) No 111/2005 to subject IMDPAM and the identified esters of BMK glycidic acid and PMK glycidic acid to the harmonised control and monitoring measures provided for by those regulations.
  • Measures to control access to newly scheduled substances under Regulations (EC) No 273/2004 and (EC) No 111/2005 should enter into force as soon as possible to prevent the use of those drug precursors for the production and placing on the market of illicit drugs.
  • Against this background, Parliament declared that it has no objections to the delegated regulation.
2024-06-03Show (2) Changes | Timetravel
docs/2
date
2024-04-23T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0314_EN.html title: T9-0314/2024
type
Text adopted by Parliament, single reading
body
EP
events/4/summary
  • The European Parliament decided to raise no objections to the Commission delegated regulation of 28 February 2024 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of the drug precursor Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (IMDPAM) and other substances in the list of scheduled substances.
  • The EU legislative framework on measures to control access to substances used in the manufacture of illicit drugs must be continuously updated to counter the proliferation of the so-called ‘designer precursors’, which are close chemical relatives of traditional drug precursors created to circumvent existing rules.
  • The sodium salt of Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (IMDPAM) has been identified as a newly developed drug precursor used in the production of MDMA (3,4-methylenedioxymethamphetamine), commonly known as ‘ecstasy’. Seven esters of 2-methyl-3-phenyloxirane-2-carboxylic acid (BMK glycidic acid) and six esters of 3-(1,3-benzodioxol-5-yl)-2-methyl-oxirane-2-carboxylic acid (PMK glycidic acid) have been identified as possible substitutes of BMK glycidic acid and PMK glycidic acid, which are controlled precursors under EU law, in the production of illicit drugs such as MDMA, methamphetamine and amphetamine.
  • It is necessary to amend the list of scheduled substances included in Annex I to Regulation (EC) No 273/2004 and in the Annex to Regulation (EC) No 111/2005 to subject IMDPAM and the identified esters of BMK glycidic acid and PMK glycidic acid to the harmonised control and monitoring measures provided for by those regulations.
  • Measures to control access to newly scheduled substances under Regulations (EC) No 273/2004 and (EC) No 111/2005 should enter into force as soon as possible to prevent the use of those drug precursors for the production and placing on the market of illicit drugs.
  • Against this background, Parliament declared that it has no objections to the delegated regulation.
2024-06-02Show (2) Changes | Timetravel
docs/2
date
2024-04-23T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0314_EN.html title: T9-0314/2024
type
Text adopted by Parliament, single reading
body
EP
events/4/summary
  • The European Parliament decided to raise no objections to the Commission delegated regulation of 28 February 2024 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of the drug precursor Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (IMDPAM) and other substances in the list of scheduled substances.
  • The EU legislative framework on measures to control access to substances used in the manufacture of illicit drugs must be continuously updated to counter the proliferation of the so-called ‘designer precursors’, which are close chemical relatives of traditional drug precursors created to circumvent existing rules.
  • The sodium salt of Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (IMDPAM) has been identified as a newly developed drug precursor used in the production of MDMA (3,4-methylenedioxymethamphetamine), commonly known as ‘ecstasy’. Seven esters of 2-methyl-3-phenyloxirane-2-carboxylic acid (BMK glycidic acid) and six esters of 3-(1,3-benzodioxol-5-yl)-2-methyl-oxirane-2-carboxylic acid (PMK glycidic acid) have been identified as possible substitutes of BMK glycidic acid and PMK glycidic acid, which are controlled precursors under EU law, in the production of illicit drugs such as MDMA, methamphetamine and amphetamine.
  • It is necessary to amend the list of scheduled substances included in Annex I to Regulation (EC) No 273/2004 and in the Annex to Regulation (EC) No 111/2005 to subject IMDPAM and the identified esters of BMK glycidic acid and PMK glycidic acid to the harmonised control and monitoring measures provided for by those regulations.
  • Measures to control access to newly scheduled substances under Regulations (EC) No 273/2004 and (EC) No 111/2005 should enter into force as soon as possible to prevent the use of those drug precursors for the production and placing on the market of illicit drugs.
  • Against this background, Parliament declared that it has no objections to the delegated regulation.
2024-06-01Show (2) Changes | Timetravel
docs/2
date
2024-04-23T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0314_EN.html title: T9-0314/2024
type
Text adopted by Parliament, single reading
body
EP
events/4/summary
  • The European Parliament decided to raise no objections to the Commission delegated regulation of 28 February 2024 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of the drug precursor Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (IMDPAM) and other substances in the list of scheduled substances.
  • The EU legislative framework on measures to control access to substances used in the manufacture of illicit drugs must be continuously updated to counter the proliferation of the so-called ‘designer precursors’, which are close chemical relatives of traditional drug precursors created to circumvent existing rules.
  • The sodium salt of Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (IMDPAM) has been identified as a newly developed drug precursor used in the production of MDMA (3,4-methylenedioxymethamphetamine), commonly known as ‘ecstasy’. Seven esters of 2-methyl-3-phenyloxirane-2-carboxylic acid (BMK glycidic acid) and six esters of 3-(1,3-benzodioxol-5-yl)-2-methyl-oxirane-2-carboxylic acid (PMK glycidic acid) have been identified as possible substitutes of BMK glycidic acid and PMK glycidic acid, which are controlled precursors under EU law, in the production of illicit drugs such as MDMA, methamphetamine and amphetamine.
  • It is necessary to amend the list of scheduled substances included in Annex I to Regulation (EC) No 273/2004 and in the Annex to Regulation (EC) No 111/2005 to subject IMDPAM and the identified esters of BMK glycidic acid and PMK glycidic acid to the harmonised control and monitoring measures provided for by those regulations.
  • Measures to control access to newly scheduled substances under Regulations (EC) No 273/2004 and (EC) No 111/2005 should enter into force as soon as possible to prevent the use of those drug precursors for the production and placing on the market of illicit drugs.
  • Against this background, Parliament declared that it has no objections to the delegated regulation.
2024-05-31Show (2) Changes | Timetravel
docs/2
date
2024-04-23T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0314_EN.html title: T9-0314/2024
type
Text adopted by Parliament, single reading
body
EP
events/4/summary
  • The European Parliament decided to raise no objections to the Commission delegated regulation of 28 February 2024 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of the drug precursor Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (IMDPAM) and other substances in the list of scheduled substances.
  • The EU legislative framework on measures to control access to substances used in the manufacture of illicit drugs must be continuously updated to counter the proliferation of the so-called ‘designer precursors’, which are close chemical relatives of traditional drug precursors created to circumvent existing rules.
  • The sodium salt of Isopropylidene (2-(3,4-methylenedioxyphenyl)acetyl)malonate (IMDPAM) has been identified as a newly developed drug precursor used in the production of MDMA (3,4-methylenedioxymethamphetamine), commonly known as ‘ecstasy’. Seven esters of 2-methyl-3-phenyloxirane-2-carboxylic acid (BMK glycidic acid) and six esters of 3-(1,3-benzodioxol-5-yl)-2-methyl-oxirane-2-carboxylic acid (PMK glycidic acid) have been identified as possible substitutes of BMK glycidic acid and PMK glycidic acid, which are controlled precursors under EU law, in the production of illicit drugs such as MDMA, methamphetamine and amphetamine.
  • It is necessary to amend the list of scheduled substances included in Annex I to Regulation (EC) No 273/2004 and in the Annex to Regulation (EC) No 111/2005 to subject IMDPAM and the identified esters of BMK glycidic acid and PMK glycidic acid to the harmonised control and monitoring measures provided for by those regulations.
  • Measures to control access to newly scheduled substances under Regulations (EC) No 273/2004 and (EC) No 111/2005 should enter into force as soon as possible to prevent the use of those drug precursors for the production and placing on the market of illicit drugs.
  • Against this background, Parliament declared that it has no objections to the delegated regulation.
2024-04-27Show (4) Changes | Timetravel
docs/2
date
2024-04-23T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0314_EN.html title: T9-0314/2024
type
Text adopted by Parliament, single reading
body
EP
events/4
date
2024-04-23T00:00:00
type
Decision by Parliament
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0314_EN.html title: T9-0314/2024
forecasts
  • date: 2024-04-22T00:00:00 title: Indicative plenary sitting date
procedure/stage_reached
Old
Awaiting Parliament's vote
New
Procedure completed - delegated act enters into force
2024-04-26Show (4) Changes | Timetravel
docs/2
date
2024-04-23T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0314_EN.html title: T9-0314/2024
type
Text adopted by Parliament, single reading
body
EP
events/4
date
2024-04-23T00:00:00
type
Decision by Parliament
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0314_EN.html title: T9-0314/2024
forecasts
  • date: 2024-04-22T00:00:00 title: Indicative plenary sitting date
procedure/stage_reached
Old
Awaiting Parliament's vote
New
Procedure completed - delegated act enters into force
2024-04-25Show (4) Changes | Timetravel
docs/2
date
2024-04-23T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0314_EN.html title: T9-0314/2024
type
Text adopted by Parliament, single reading
body
EP
events/4
date
2024-04-23T00:00:00
type
Decision by Parliament
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-9-2024-0314_EN.html title: T9-0314/2024
forecasts
  • date: 2024-04-22T00:00:00 title: Indicative plenary sitting date
procedure/stage_reached
Old
Awaiting Parliament's vote
New
Procedure completed - delegated act enters into force
2024-04-24Show (1) Changes | Timetravel
forecasts
  • date: 2024-04-22T00:00:00 title: Indicative plenary sitting date
2024-04-18Show (1) Changes | Timetravel
procedure/stage_reached
Old
Awaiting committee decision
New
Awaiting Parliament's vote
2024-04-17Show (5) Changes | Timetravel
committees/0/rapporteur
  • name: LÓPEZ AGUILAR Juan Fernando date: 2024-04-04T00:00:00 group: Group of Progressive Alliance of Socialists and Democrats abbr: S&D
docs/1
date
2024-04-10T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/B-9-2024-0213_EN.html title: B9-0213/2024
type
Recommendation for early non-objection of delegated act
body
EP
events/3
date
2024-04-12T00:00:00
type
Delegated act not objected by Council
body
CSL
forecasts
  • date: 2024-04-22T00:00:00 title: Indicative plenary sitting date
procedure/legal_basis
  • Rules of Procedure EP 0111-p6
2024-04-16Show (5) Changes | Timetravel
committees/0/rapporteur
  • name: LÓPEZ AGUILAR Juan Fernando date: 2024-04-04T00:00:00 group: Group of Progressive Alliance of Socialists and Democrats abbr: S&D
docs/1
date
2024-04-10T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/B-9-2024-0213_EN.html title: B9-0213/2024
type
Recommendation for early non-objection of delegated act
body
EP
events/3
date
2024-04-12T00:00:00
type
Delegated act not objected by Council
body
CSL
forecasts
  • date: 2024-04-22T00:00:00 title: Indicative plenary sitting date
procedure/legal_basis
  • Rules of Procedure EP 0111-p6
2024-04-15Show (5) Changes | Timetravel
committees/0/rapporteur
  • name: LÓPEZ AGUILAR Juan Fernando date: 2024-04-04T00:00:00 group: Group of Progressive Alliance of Socialists and Democrats abbr: S&D
docs/1
date
2024-04-10T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/B-9-2024-0213_EN.html title: B9-0213/2024
type
Recommendation for early non-objection of delegated act
body
EP
events/3
date
2024-04-12T00:00:00
type
Delegated act not objected by Council
body
CSL
forecasts
  • date: 2024-04-22T00:00:00 title: Indicative plenary sitting date
procedure/legal_basis
  • Rules of Procedure EP 0111-p6
2024-04-13Show (4) Changes | Timetravel
committees/0/rapporteur
  • name: LÓPEZ AGUILAR Juan Fernando date: 2024-04-04T00:00:00 group: Group of Progressive Alliance of Socialists and Democrats abbr: S&D
docs/1
date
2024-04-10T00:00:00
docs
url: https://www.europarl.europa.eu/doceo/document/B-9-2024-0213_EN.html title: B9-0213/2024
type
Recommendation for early non-objection of delegated act
body
EP
forecasts
  • date: 2024-04-22T00:00:00 title: Indicative plenary sitting date
procedure/legal_basis
  • Rules of Procedure EP 0111-p6
2024-04-12Show (4) Changes | Timetravel
committees/0/rapporteur
  • name: LÓPEZ AGUILAR Juan Fernando date: 2024-04-04T00:00:00 group: Group of Progressive Alliance of Socialists and Democrats abbr: S&D
docs/1
date
2024-04-10T00:00:00
docs
title: B9-0213/2024
type
Recommendation for early non-objection of delegated act
body
EP
forecasts
  • date: 2024-04-22T00:00:00 title: Indicative plenary sitting date
procedure/legal_basis
  • Rules of Procedure EP 0111-p6
2024-04-11Show (1) Changes | Timetravel
committees/0/rapporteur
  • name: LÓPEZ AGUILAR Juan Fernando date: 2024-04-04T00:00:00 group: Group of Progressive Alliance of Socialists and Democrats abbr: S&D
2024-04-10Show (1) Changes | Timetravel
committees/0/rapporteur
  • name: LÓPEZ AGUILAR Juan Fernando date: 2024-04-04T00:00:00 group: Group of Progressive Alliance of Socialists and Democrats abbr: S&D
2024-03-15Show (3) Changes | Timetravel
events/2
date
2024-03-13T00:00:00
type
Committee referral announced in Parliament
body
EP
procedure/dossier_of_the_committee
  • LIBE/9/14299
procedure/stage_reached
Old
Preparatory phase in Parliament
New
Awaiting committee decision
2024-03-01Show (2) Changes
docs/0/docs/0/url
https://webgate.ec.europa.eu/regdel/web/delegatedActsLinks/C(2024)01219
events/0/docs/0/url
https://webgate.ec.europa.eu/regdel/web/delegatedActsLinks/C(2024)01219
@parltrack
@parltrack@eupolicy.social
[javascript protected email address]
code AGPLv3.0+
data ODBLv1.0
site content CC-By-Sa-3.0

ParlTrack - 2011-2024

© European Union, 2011 – Source: European Parliament
Hosted by AS250.net Foundation